A Gene Expression Profile Test for the Differential Diagnosis of Ovarian Versus Endometrial Cancers by Lal, Anita et al.
Oncotarget 2012; 3:  212-223 212 www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/  Oncotarget, February, Vol.3, No 2
A Gene Expression Profile Test for the Differential Diagnosis of 
Ovarian Versus Endometrial Cancers
Anita Lal1, Rebecca Panos1, Mira Marjanovic1, Michael Walker1, Eloisa Fuentes1, 
Daniel S Kapp2, W. David Henner1, Ljubomir J. Buturovic1 and Meredith Halks‑Miller1
1 Pathwork Diagnostics, Redwood City, CA
2 Department of Radiation Oncology, Stanford University, Stanford, CA
Correspondence to: Anita Lal, email: alal@pathworkdx.com 
Keywords: gene expression, tissue of origin, endometrial cancer, ovarian cancer, diagnostic test
Received:  February 15, 2012,  Accepted: February 21, 2012,  Published: February 23, 2012
Copyright: © Lal et al.  This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT:
We  have  developed  a  gene  expression  profile  test  (Pathwork  Tissue  of  Origin 
Endometrial Test) that distinguishes primary epithelial ovarian and endometrial 
cancers  in  formalin‑fixed,  paraffin‑embedded  (FFPE)  specimens  using  a  316–
gene classification model. The test was validated in a blinded study using a pre‑
specified algorithm and microarray files for 75 metastatic, poorly differentiated or 
undifferentiated specimens with a known ovarian or endometrial cancer diagnosis. 
Measures of test performance include a 94.7% overall agreement with the known 
diagnosis, an area under the ROC curve (AUC) of 0.997 and a diagnostic odds ratio 
(DOR) of 406. Ovarian cancers (n=30) gave an agreement of 96.7% with the known 
diagnosis while endometrial cancers (n=45) gave an agreement of 93.3%. In a 
precision study, concordance in test results was 100%. Reproducibility in test results 
between three laboratories was 94.3%. The Tissue of Origin Endometrial Test can 
aid in resolving important differential diagnostic questions in gynecologic oncology.
INTRODUCTION
Accurate diagnosis of ovarian and endometrial 
cancer impacts not only prognosis and clinical 
management of these patients but also anticancer drug and 
radiation therapy choices as well as entry opportunities for 
clinical trials. Treatment regimens for endometrial cancer 
patients often include radiation therapy and possibly 
hormonal therapy. Ovarian cancer patients are typically 
managed differently from endometrial cancer patients and 
undergo meticulous surgery including aspiration of ascites 
or peritoneal lavage, attempted optimal tumor debulking 
and, if no gross extraovarian disease is visualized, random 
peritoneal biopsies [1,2]. Often, the differential diagnosis 
of ovarian versus endometrial cancers is a challenging 
problem in diagnostic gynecologic pathology. Ascertaining 
the primary gynecologic site of a metastatic carcinoma is 
sometimes difficult because specific histologic subtypes 
of ovarian and endometrial cancers appear similar on 
gross and microscopic examination. For example, ovarian 
endometrioid carcinomas, which constitute up to 13% of 
ovarian cancers, are histologically similar to endometrial 
endometrioid carcinomas [3-5]. Similarly, endometrial 
serous adenocarcinomas are commonly confused with 
ovarian serous adenocarcinomas [6]. 
Endometrial cancers commonly metastasize to 
the ovary and often mimic an ovarian primary [7,8]. In 
cases of disseminated cancers that involve both the ovary 
and the endometrium, it is often impossible to establish 
whether the cancer represents metastatic spread from 
a uterine primary, metastatic spread from an ovarian 
primary or whether it represents synchronous ovarian 
and endometrial primaries [9]. Poorly differentiated and 
undifferentiated carcinomas, in particular, can be difficult 
to diagnose accurately using morphological criteria [10]. 
There is a clear need for ancillary techniques beyond 
microscopic evaluations of routine hematoxylin and eosin 
(H&E) stained sections that would enable pathologists to 
make an accurate ovarian or endometrial cancer diagnosis. 
Immunohistochemistry (IHC) is the most commonly 
used ancillary technique in gynecologic pathology. 
Immunohistochemical biomarkers are typically not 
specific for a single tumor type necessitating the use of a 
panel of antibodies [7,11,12]. In the case of ovarian and Oncotarget 2012; 3:  212-223 213 www.impactjournals.com/oncotarget
endometrial cancers, immunohistochemical biomarkers 
have  overlapping  immunoreactivities  with  specific 
histologic subtypes of both ovarian and endometrial 
cancers. For example, p16 immunoreactivity is observed 
in both ovarian and endometrial serous adenocarcinomas 
and is largely absent from both ovarian and endometrial 
endometrioid adenocarcinomas [13]. Yet other biomarkers, 
such as WT1, are specific to only a single histologic 
subtype within either ovarian or endometrial cancers. 
Ovarian serous adenocarcinomas exhibit positive 
immunostaining with WT1 while endometrial serous 
carcinomas and both ovarian and endometrial endometrioid 
adenocarcinomas show negative immunostaining with 
WT1 [6]. A large proportion of ovarian cancers, with 
the exception of ovarian mucinous adenocarcinomas, 
are positive for estrogen and progesterone receptors 
[13]. However, a considerable proportion of endometrial 
cancers are also positive for these receptors precluding the 
utility of these common biomarkers to distinguish ovarian 
from endometrial cancers [14]. Given the morphologic 
heterogeneity of ovarian and endometrial cancers and the 
complex pattern of expression of immunohistochemical 
biomarkers in these cancers, additional diagnostic 
approaches are required for their accurate classification.
In addition to the challenges that pathologists 
face in using IHC to distinguish between ovarian and 
endometrial cancer, validation of antibodies used in IHC is 
expensive, time-consuming and performed inconsistently. 
Interpretation and reporting of IHC results are also 
subjective and user-dependent. Molecular diagnostic tests 
that use gene expression profiling with microarrays to 
classify cancers according to their primary sites are now 
a feasible tool for cancer diagnosis [15-18]. Advances 
in gene annotation and array design along with the use 
of standardized protocols and array platforms across 
laboratories have made microarray-based gene expression 
profiling extremely reproducible [16,19-21]. These assays 
have the advantage of measuring the expression of a 
multitude of biomarkers simultaneously [22]. Additionally, 
the use of RNA from formalin-fixed paraffin embedded 
(FFPE) tissue in microarray-based diagnostics has become 
more common, considerably expanding the utility of these 
diagnostic tests [16,23-25]. 
We have developed a microarray-based diagnostic 
test, the Pathwork Tissue of Origin Endometrial Test 
(Pathwork Diagnostics, Redwood City, CA), that can 
be used for the differential diagnosis of ovarian versus 
endometrial cancers. We present data from a blinded, 
multicenter clinical validation study showing that the 
Tissue of Origin Endometrial Test has a high accuracy 
of 94.7% in classifying ovarian and endometrial cancers. 
We also show that inter-laboratory reproducibility of test 
results was 94.3%. The Tissue of Origin Endometrial Test 
is a novel molecular diagnostic test that is expected to be a 
valuable aid to physicians treating patients of gynecologic 
cancers. 
RESULTS
The Tissue of Origin Endometrial Test
The Tissue of Origin Endometrial Test measures 
the expression of 375 probesets (316 independent genes) 
that  serve  as  markers  during  classification  of  ovarian 
and  endometrial  cancers.  Sensitivity,  specificity  and 
AUC values for the training data were calculated using 
cross-validation for different numbers of classification 
probesets (Figure 2). The performance curves converge 
to their asymptotic values at just under 400 probesets. 
We chose the simplest model in our judgment consisting 
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GUIDE TO REPORT INTERPRETATION
The Similarity Score (SS) is a measure of the similarity of the RNA expression pattern of the specimen to the RNA expression patterns 
of endometrial and ovarian tumor tissues. 
• Two SS are provided, one for endometrial origin and one for ovarian origin; the scores add up to 100. 
• A Similarity Score of ≤ 20 rules out that tissue type with > 99% probability (95% CI: 94.6%, 100%). 
• The higher the SS, the more likely it represents the tissue of origin of the cancer. 
Because the test has been validated to distinguish between endometrial and ovarian cancers only, it should be used only when there 
is reasonable confidence that the tumor is either ovarian or endometrial in origin. 
Figure 1: A sample Tissue of Origin Endometrial Test report. The report presents 2 similarity scores, one for ovarian and one for 
endometrial cancers. The two similarity scores add up to 100. The tissue type with the higher similarity score is the more likely tissue of 
origin. In the sample shown, ovarian cancer with a similarity score of 96.9 is the more likely tissue of origin.Oncotarget 2012; 3:  212-223 214 www.impactjournals.com/oncotarget
of 375 probesets and providing maximum achievable 
predictive performance on this platform. Even though the 
classification markers are empirically selected by machine 
learning, they included several genes that were previously 
known to have a function in the biology of ovarian and 
endometrial cancers (Table 2). Homeobox A10 (HOXA10) 
and Homeobox A11 (HOXA11) have previously been 
shown to be overexpressed in ovarian cancers, and play 
a role in stimulating tumor growth and determining the 
histologic identity of epithelial ovarian cancers [26-28]. 
Specific  homologs  of  the  Kallikrien  peptidases  have 
been evaluated as serum diagnostic markers for the early 
detection of both ovarian and endometrial cancers [29-
32]. WT1 is an immunohistochemical biomarker used 
for distinguishing ovarian versus endometrial serous 
adenocarcinomas [6].
Processing of Clinical Validation Specimens
Tissue sections from 82 specimens were processed 
for total RNA. Thirty nanograms of total RNA is a 
required quality metrics to perform the Tissue of Origin 
Endometrial Test. Eighty one specimens that yielded at 
least 30 ng of total RNA at a concentration of  ≥ 9.5 ng/
µl and had an A260/A280 ratio of  ≥ 1.0 were processed 
further. Of these, 80 specimens yielded at least 2.5 µg 
of biotinylated cDNA, which is a required cDNA quality 
metrics, and were hybridized to Pathchip microarrays. 
Of the 80 specimens, 79 specimens passed pre-specified 
microarray data quality criteria. In all, 96.3% (79/82) of 
FFPE specimens processed passed all quality criteria for 
the Tissue of Origin Endometrial Test. Four additional 
specimens were subsequently removed because the 
specimen vendor did not follow standard quality control 
procedures and these specimens did not meet specimen 
entry criteria of a known ovarian or endometrial clinical 
diagnosis. A total of 75 specimens were used in data 
analysis.
Performance of the Tissue of Origin Endometrial 
Test
The clinical validation study followed a Bayesian 
adaptive design. Testing was terminated at Look1 because 
the acceptance criteria of mean PPA and lower bound of 
the 95% credible interval for both ovarian and endometrial 
cancers exceeded pre-specified threshold values at this 
interim analysis (Supplementary Table 2). The positive 
percent agreement (PPA) and percent non-agreement 
with 95% confidence intervals for the Tissue of Origin 
Endometrial Test are summarized in Table 3. The overall 
Figure 2: Determination of the optimal number of classification probesets for the Tissue of Origin Endometrial Test. 
Sensitivity, Specificity and AUC were analyzed using cross-validation of training data for different numbers of classification probesets. A 
model with 375 probesets was chosen because performance curves had reached asymptotic values and maximal predictive performance 
was achieved.Oncotarget 2012; 3:  212-223 215 www.impactjournals.com/oncotarget
agreement of the Tissue of Origin Endometrial Test results 
with the known clinical diagnosis was 94.7% (95% CI, 
86.9% to 98.5%). Ovarian cancers had a higher PPA of 
96.7% compared to endometrial cancers that had a PPA of 
93.3% (Fisher’s exact test, p=0.646; Table 3). 
An ROC for the Tissue of Origin Endometrial Test 
was plotted and an AUC of 0.997 was obtained indicating 
high discriminatory performance between ovarian and 
endometrial cancers (Figure 3A). The DOR of 406 also 
indicated that the Tissue of Origin Endometrial Test had 
good discrimination between ovarian and endometrial 
cancers. 
A distribution plot of the endometrial similarity 
scores in bins of 10 for the 75 clinical validation 
specimens is plotted in Figure 3B. Since the sum of the 
similarity scores for endometrial and ovarian tissue types 
is 100, the higher the endometrial similarity score the 
lower the ovarian similarity score. The median higher 
similarity score for cases that gave agreements with the 
known clinical diagnosis is 95.6 (range - 70.4-99.3) while 
the median higher similarity score for cases that gave 
non-agreements was much lower at 60.8 (range - 59.6-
71.6). Eighty nine percent (67/75) of the specimens in the 
validation set had a higher similarity score that was greater 
than 80. Among the ovarian predictions, 25/30 specimens 
had similarity scores of >90 while 31/45 specimens that 
gave endometrial predictions had similarity scores of 
>90. A clear separation in the higher similarity score was 
observed for the vast majority of ovarian and endometrial 
cancer cases (Figure 3B). When the higher similarity score 
is greater than 80, the probability of agreement between 
the Tissue of Origin Endometrial Test result and the 
known clinical diagnosis was 100%. This also indicates 
that a similarity score of ≤ 20 rules out that tissue type 
with > 99% probability (95% CI, 94.6% to 100%). 
Performance of the Tissue of Origin Endometrial 
Test According to Specimen Attributes
The majority of the specimens used for clinical 
validation were acquired in the prior 2 years (Table 4). 
For specimens >2 years old, Tissue of Origin Endometrial 
Test performance was 90.5%. This group included 
two specimens that were 7 years old and both of these 
specimens gave accurate Tissue of Origin Endometrial 
Test results. The age of the specimen did not affect Test 
performance.
Test performance was also consistent at all levels of 
viable percent tumor above the minimal threshold (≥ 60%) 
of tumor content required for specimen entry into the 
Tissue of Origin Endometrial Test (Table 4). Specimens 
in the 60% to 70% tumor content bin had a PPA of 100%. 
The presence of up to 40% necrosis in the specimen under 
analysis did not diminish performance of the Tissue of 
Origin Endometrial Test (Table 4). 
Performance of the Tissue of Origin Endometrial 
Test According to Patient and Cancer Attributes
The age range of patients from whom validation 
specimens were obtained was wide with the majority of 
the patients being 50 to 80 years old (Table 5). The Tissue 
of Origin Endometrial Test had good performance for all 
patient age groups (Table 5). The grade of the cancer was 
known for 70/75 cases included in the validation study. 
Since primary tumors in the validation set were solely 
composed of poorly differentiated to undifferentiated 
cancers, the vast majority of cases were Grade 3 cancers. 
The Tissue of Origin Endometrial Test had high accuracy 
A                                  B 
 
Figure 3: Performance of the Tissue of Origin Endometrial Test. An ROC curve (A) for the Tissue of Origin Endometrial Test 
using results from the independent validation specimens gives an AUC value of 0.997. Distribution of similarity scores (B) obtained for the 
validation specimens shows clear separation of ovarian and endometrial cancer predictions. Oncotarget 2012; 3:  212-223 216 www.impactjournals.com/oncotarget
Tissue Type Included Histologic Subtypes* Excluded Histologic Subtypes*
Endometrial
Adenocarcinoma, NOS
Clear cell adenocarcinoma Endometrial stromal sarcoma
Endometrioid adenocarcinoma Leiomyosarcoma
Serous adenocarcinoma
Mixed cell adenocarcinoma
Malignant müllerian mixed 
tumor
Ovarian
Adenocarcinoma, NOS
Clear cell adenocarcinoma Primitive germ cell tumors
Endometrioid adenocarcinoma Sex cord-stromal tumors
Mixed epithelial tumor Malignant Brenner tumor
Mucinous adenocarcinoma
Malignant müllerian mixed 
tumor
Serous adenocarcinoma
Serous surface papillary 
adenocarcinoma
Undifferentiated carcinoma
* Histologic subtypes are listed using WHO nomenclature
Table 1: Morphologies on the Tissue of Origin Endometrial Test Panel 
Marker 
Rank
Probeset ID
Gene 
Symbol
Gene Name Cellular Function
1 213147_at HOXA10* Homeobox A10 Transcription Factor
2 213707_s_at DLX5
Distal-less homeobox 
5
Transcription Factor
3 213823_at HOXA11* Homeobox A11 Transcription Factor
4 204733_at KLK6*
Kallikrein-related 
peptidase 6
Serine protease
5 206125_s_at KLK8*
Kallikrein-related 
peptidase 8
Serine protease
6 207076_s_at ASS1
Argininosuccinate 
synthase 1
Arginine Biosynthesis
7 205778_at KLK7*
Kallikrein-related 
peptidase 7
Serine protease
8 32625_at NPR1
Natriuretic peptide 
receptor A/ guanylate 
cyclase A
9 214844_s_at DOK5 Docking protein 5
Adaptor protein of 
MAP Kinase Pathway
10 206067_s_at WT1*$ Wilms tumor 1 Transcription Factor
*Previously known to have a functional role in ovarian and/or endometrial cancers 
$Biomarker known to distinguish ovarian and endometrial serous adenocarcinomas
Table 2: Top 10 Biomarkers in the Tissue of Origin Endometrial Test 
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for both Grade 3 ovarian and Grade 3 endometrial cancers 
(Table 5). Tissue of Origin Endometrial Test performance 
was good with both metastatic specimens (90.5%; n=21) 
and with poorly differentiated and undifferentiated 
primary tumors (96.3%; n=54) (Table 5). There were a 
larger number of metastatic ovarian tumors compared to 
metastatic endometrial tumors (Table 5). The difference 
in PPA between metastatic specimens of ovarian (94.1%; 
n=17) and endometrial (75%; n=4) origins is not 
statistically significant (Fisher’s exact test, p=0.3524). The 
majority of metastatic samples (13/21) were biopsied from 
the omentum and these samples had a 100% (95% CI, 75.3-
100) agreement with the known clinical diagnosis. Other 
metastatic specimens were either lung (n=4) or soft tissue 
(n=4) biopsies. Both of these biopsy sites gave three (of 
4) agreements each with the available clinical diagnosis. 
The  stage  of  the  cancer  was  known  for  50/75  cases 
included in the validation set. The majority of ovarian 
cases used in the validation study were Stage III and IV 
cancers (n=21) while the majority of endometrial cases 
were Stage I  cancers (n=15). However, the validation set 
included cases that were representative of all stages of 
ovarian and endometrial cancers and the Tissue of Origin 
Endometrial Test had good performance with all stages 
of ovarian and endometrial cancers. The validation set 
included both ovarian serous adenocarcinomas (n=22) and 
endometrial serous adenocarcinomas (n=7). The Tissue 
of Origin Endometrial Test clearly distinguished serous 
adenocarcinomas of ovarian and endometrial origins 
even when a clear distinction could not be made based 
on histologic criteria (Table 5, Figure 4). The difference 
in PPA between ovarian serous adenocarcinomas (100%) 
and endometrial serous adenocarcinomas (71.4%) was not 
statistically significant (Fisher’s exact test, p=0.0517). The 
Tissue of Origin Endometrial Test could also distinguish 
between poorly differentiated ovarian and poorly 
differentiated endometrial cancers (Figure 4). 
Figure 4: Distinction of ovarian and endometrial cancers by the Tissue of Origin Endometrial Test. H&E stained 
sections (A, B, C and D) of an ovarian serous adenocarcinoma (A), an endometrial serous adenocarcinoma (B), a poorly differentiated 
ovarian adenocarcinoma (C) and a poorly differentiated endometrial adenocarcinoma (D) from the validation specimens show similar 
morphologic appearance of ovarian and endometrial serous adenocarcinomas (A and B) and ovarian and endometrial poorly differentiated 
adenocarcinomas (C and D). The Tissue of Origin Endometrial Test clearly distinguished between these tumors. The Tissue of Origin 
Endometrial Test result was ovarian with a similarity score of 96.4 for the ovarian serous adenocarcinoma (A), ovarian with a similarity 
score of 90.2 for the poorly differentiated ovarian adenocarcinoms (C), endometrial with a similarity score of 90.5 for the endometrial 
serous adenocarcinoma (B) and endometrial with a similarity score of 87.8 for the poorly differentiated endometrial adenocarcinoma (D). 
All images are at the same magnification. Bar = 50 µm.
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Reproducibility of the Tissue of Origin 
Endometrial Test
Intra-site reproducibility (precision) was assessed 
by performing pairwise comparisons of the Tissue of 
Origin Endometrial Test results obtained from 3 adjacent 
sections from the same tissue block processed in the same 
run. Percent concordance in test results was 100% for each 
pairwise comparison (Table 6). The median coefficient of 
variation (CV%) of the similarity score for the known 
clinical diagnosis was 1.38 (range 0.32 to 8.79). The 
value of Kappa (Κ) statistics was 1.0 for all three pairwise 
comparisons indicating perfect agreement in the Tissue 
of Origin Endometrial Test results between sections 
processed in the same run.
Pairwise comparisons of Tissue of Origin 
Endometrial test results for adjacent sections from 30 
specimens processed at three laboratories (PWDL, EA and 
GLGC) were performed to assess inter-site reproducibility. 
The percent concordance in test results for PWDL versus 
EA was 93.3%, for PWDL versus GLGC was 96.6% and 
for EA versus GLGC was 93.1% (Table 6). The median 
CV% of the similarity score for the known clinical 
diagnosis was 3.02 (range - 0.23 to 46.9%). Twenty seven 
specimens had Tissue of Origin Endometrial Test results 
that were concordant at all 3 sites, and all 27 specimens 
had CV% that were less than 10. Kappa (Κ) statistics 
for agreement for PWDL versus EA was 0.87 (95% CI, 
0.66-1.00), for PWDL versus GLGC was 0.93 (95% CI, 
0.76-1.00) and for EA versus GLGC was 0.86 (95% CI, 
0.65-1.00), indicating a very good agreement (Κ ≥ 0.81) 
in Tissue of Origin Endometrial Test results between the 
three sites.
DISCUSSION
The Pathwork Tissue of Origin Endometrial Test 
is  the  first  microarray-based  diagnostic  test  that  has 
been successfully used to differentiate ovarian from 
endometrial cancers. Performance was evaluated in an 
independent set of specimens that were solely composed 
of either metastatic cancers or poorly differentiated 
and undifferentiated primary cancers [10]. The Tissue 
of Origin Endometrial Test showed a high degree of 
agreement with the clinically available diagnosis for these 
challenging specimens, accurately identifying the primary 
site for 94.7% of ovarian and endometrial cancers. In 
addition to the high accuracy, there was a clear separation 
in similarity scores obtained for the 2 tissue types.
The Tissue of Origin Endometrial Test uses 375 
probesets (316 independent genes) to classify ovarian 
and endometrial cancers. These classification biomarkers 
were chosen based upon maximal performance observed 
with  the  training  data.  The  classification  biomarkers 
were empirically selected. Nonetheless, they included 
several genes with known functional roles in ovarian 
and/or  endometrial  cancers  as  well  as  the  common 
immunohistochemical biomarker, WT1, that is used 
to distinguish ovarian serous and endometrial serous 
adenocarcinomas [6,29,31]. 
The Tissue of Origin Endometrial Test utilizes 
FFPE specimens, the most commonly available clinical 
specimen. Additionally, the success rate for processing 
of FFPE specimens that had met specimen entry criteria 
was 96.3%. The use of FFPE along with a high processing 
success rate is advantageous in the clinical setting, and will 
allow for wide usage of the Tissue of Origin Endometrial 
Test.  
The Tissue of Origin Endometrial Test includes 
14 different WHO histologic subtypes of ovarian 
and endometrial cancers. Poorly differentiated 
adenocarcinomas of ovarian and endometrial origins can 
be difficult to distinguish because of similar histologic 
appearances. In addition, endometrioid ovarian and 
endometrioid endometrial subtypes as well as serous 
ovarian and serous endometrial subtypes are histologically 
similar and their primary sites can be difficult to diagnose 
[3,4,6]. The Tissue of Origin Endometrial Test training 
and test sets included both ovarian and endometrial serous 
histologic subtypes and also both ovarian and endometrial 
endometrioid histologic subtypes. Test set analysis showed 
that the Tissue of Origin Endometrial Test can distinguish 
between ovarian and endometrial endometrioid cancers 
and also between ovarian and endometrial serous cancers 
(data not shown). The Tissue of Origin Endometrial Test 
validation set did not include any ovarian endometrioid 
carcinomas but included both ovarian serous (N=22) and 
endometrial serous (N=7) carcinomas. The test identified 
all ovarian serous cancers and 5 endometrial serous 
cancers accurately. Thus, the Tissue of Origin Endometrial 
test can distinguish serous morphologies from ovarian and 
endometrial origins. It also performed well with poorly 
differentiated cancers of ovarian and endometrial origins.
In this study, we present data validating the accuracy 
and reproducibility of the Tissue of Origin Endometrial 
Test. Clinical management and treatment choices for 
Known 
Clinical 
Diagnosis
Positive Percent 
Agreement 
Percent (ratio)
[95% Confidence 
Interval]
Percent Non-Agreement 
Percent (ratio)
[95% Confidence 
Interval]
Endometrial
93.3 (42/45)
[81.7-98.6]
6.7 (3/45)
[1.4-18.3]
Ovarian
96.7 (29/30)
[82.8-99.9]
3.3 (1/30)
[0.1-17.2]
Overall
94.7 (71/75)
[86.9-98.5]
5.3 (4/75)
[1.5-13.1]
Table 3: Accuracy of the Tissue of Origin 
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ovarian and endometrial cancer patients are different 
with endometrial cancer patients often receiving radiation 
therapy and possibly hormonal therapy. Future studies 
and clinical use of the Tissue of Origin Endometrial Test 
will ultimately determine how this test impacts clinical 
management of ovarian and endometrial cancer patients. 
We anticipate the Tissue of Origin Endometrial Test 
to have great clinical value for patients whose cancers 
involve both the ovary and uterus. In these cases, the 
test would distinguish between simultaneous primary 
malignancies or metastatic spread from either the ovary or 
the endometrium. As more targeted therapies specific for 
ovarian or endometrial cancers are developed, the Tissue 
of Origin Endometrial Test is expected to have increasing 
impact on the clinical outcome and life expectancy of 
these patients.
METHODS
FFPE Tumor Specimens 
FFPE tumor specimens, acquired using Institutional 
Review Board-approved procedures, were obtained from 
six different human tumor tissue banks. All specimens 
were excisional biopsies, had a known ovarian or 
endometrial cancer clinical diagnosis and were from one 
of the included morphologies (see Table 1) on the Tissue 
of Origin Endometrial Test panel. All specimens had a 
known biopsy site and were either metastatic tumors 
or primary tumors that were poorly differentiated or 
undifferentiated. Available clinical information associated 
with the specimen including age, race, tissue dimensions 
and date (year) of resection was recorded. H&E sections 
adjacent to the tumor sample were reviewed by a 
pathologist to determine the percentage of tumor tissue, 
normal tissue and necrosis. Specimen requirement for 
entry into the Tissue of Origin Endometrial Test includes a 
minimum of 60% tumor tissue. Therefore, only specimens 
that contained at least 60% tumor tissue were used in this 
study. The set of specimens used for algorithm training 
was completely independent from the set of specimens 
used for clinical validation.
RNA Extraction, Target Preparation, and 
Microarray Processing Procedures
FFPE tumor specimens were processed as described 
in a previous study [16]. Briefly, total RNA was isolated 
from 10 µm thick sections using the Agencourt FormaPure 
system (Beckman Coulter Genomics, Beverly, MA) and 
the Ambion DNase I RNA-free kit (Life Technologies, 
Austin, TX). Total RNA concentration was assessed by 
spectrophotometry (OD 260 nm, NanoDrop, Wilmington, 
Specimen 
Attribute
Category
Definition
N
PPA
Percent, (Ratio)
[95% Confidence 
Interval]
Percent Non-
Agreement
Percent, (Ratio)
[95% Confidence 
Interval]
Age of Specimen
<1 year 24
95.8 (23/24)
[78.9-99.9]
4.2 (1/24)
[0.1-21.1]
1-2 year 30
96.7 (29/30)
[82.8-99.9]
3.3 (1/30)
[0.1-17.2]
>2 year 21
90.5 (19/21)
[69.6-98.8]
9.5 (2/21)
[1.2-30.4]
Percent Tumor 
Content
90% < x ≤ 100% 13
92.3 (12/13)
[64.0-99.8]
7.7 (1/13)
[0.2-36.0]
80% < x ≤ 90% 22
95.5 (21/22)
[77.2-99.9]
4.5 (1/22)
[0.1-22.8]
70% < x ≤ 80% 21
90.5 (19/21)
[69.6-98.8]
9.5 (2/21)
[1.2-30.4]
60% ≤ x ≤ 70% 19
100 (19/19)
[85.4-100]
0.0 (0/19)
[0.0-14.6]
Percent Necrosis 
Content
0% ≤ x < 10% 48
93.8 (45/48)
[82.8-98.7]
6.3 (3/48)
[1.3-17.2]
10% ≤ x < 20% 18
94.4 (17/18)
[72.7- 99.9]
5.6 (1/18)
[0.1-27.3]
20% ≤ x < 30% 4
100 (4/4)
[39.8-100]
0.0 (0/4)
[0.0-60.2]
30% ≤ x ≤ 40% 5
100 (5/5)
[47.8-100]
0.0 (0/5)
[0.0-52.2]
PPA, Positive percent agreement; N, Number of specimens in each category
Table 4: Tissue of Origin Endometrial Test Performance According 
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DE), and the purity was judged by the ratio of absorbance 
at 260 nm to 280 nm (A260/A280).  A minimum total RNA 
yield of 30 ng at a concentration of  ≥ 9.5 ng/µl and with 
an A260/A280 ratio of  ≥ 1.0 was required to proceed to 
target preparation. Thirty ng of total RNA was amplified 
using  the  RampUp  kit  (Genisphere,  Hatfield,  PA)  to 
generate biotin-labeled cDNA. A minimum yield of 2.5 
µg of labeled cDNA was required to proceed to microarray 
analysis. Labeled cDNA was hybridized to a Pathchip® 
microarray (manufactured by Affymetrix, Santa Clara, 
CA), and washed and stained using commercially available 
reagent kits and protocols (Affymetrix, Inc., Santa Clara, 
CA). The arrays were scanned using either the Affymetrix 
GCS3000Dx or the Affymetrix 7G Scanner. The resulting 
raw intensity data files (CEL files) were analyzed for data 
quality. Data quality was verified to meet prespecified 
quality control metrics of Overall Signal ≥ 10, Percent 
Present ≥ 5, and Regional Discontinuity ≤ 0.84, calculated 
as described previously [16]. 
Specimen Processing Sites
All specimen preparation and processing was 
performed at one of three independent processing 
laboratories: Pathwork Diagnostics Laboratory (PWDL, 
Redwood City, CA), Expression Analysis (EA, Durham, 
NC) and GeneLogic, Inc (GLGC, Gaithersburg, MA). 
PWDL and GLGC processed specimens for the clinical 
validation study; inter-site reproducibility was assessed at 
PWDL, EA and GLGC; intra-site repeatability (precision) 
was assessed at PWDL. Laboratories performing the test 
were blinded to the known clinical diagnosis. All CEL files 
were transferred to Pathwork Diagnostics for data quality 
assessment and analysis through the Tissue of Origin 
Endometrial Test. 
Patient/
Cancer Attribute
Category 
Definition
N
Ovarian PPA
Percent, (Ratio)
[95% Confidence 
Interval]
Endometrial PPA
Percent, (Ratio)
[95% Confidence 
Interval]
Overall PPA
Percent, (Ratio)
[95% Confidence 
Interval]
p-value*
Age of Patient 
(years)
30-50 9
100 (5/5)
[47.8-100]
100 (4/4)
[39.8-100]
100 (9/9)
[66.4-100]
50-60 24
100 (11/11)
[71.5-100]
100 (13/13)
[75.3-100]
100 (24/24)
[85.8-100]
60-70 28
100 (11/11)
[63.6-98.5]
88.2 (15/17)
[63.6-98.5]
92.9 (26/28)
[76.5-99.1]
0.505
70-90 14
75 (2/3)
[9.4-99.2]
90.9 (10/11)
[58.7-99.8]
85.7 (12/14)
[57.2-98.2]
0.396
Cancer Grade
Grade 1 0
Grade 2 2
100 (2/2)
[15.8-100]
100 (1/1)
[2.5-100]
100 (3/3)
[29.2-100]
Grade 3 25
96 (24/25)
[79.6-99.9]
95.2 (40/42)
[83.8-99.4]
95.5 (64/67)
[87.5-99.1]
1.000
Primary versus 
Metastatic Cancer
Metastatic 21
94.1 (16/17)
[71.3-99.9]
75.0 (3/4)
[19.4-99.4]
90.5 (19/21)
[69.6-98.8]
0.352
Primary 54
100 (13/13)
[75.3-100]
95.1 (39/41)
[83.5-99.4]
96.3 (52/54)
[87.3-99.5]
1.000
Cancer Stage
I 19
100 (4/4)
[39.8-100]
100 (15/15)
[78.2-100]
100 (19/19)
[82.4-100]
II 7
100 (3/3)
[29.2-100]
75.0 (3/4)
[19.4-99.4]
85.7 (6/7)
[42.1-99.6]
1.000
III and IV 24
95.2 (20/21)
[76.2-99.9]
66.7 (2/3)
[9.4-99.2]
91.7 (22/24)
[73.0-99.0]
0.239
Cancer 
Morphology
Serous
29 100 (22/22)
[84.6-100]
71.4 (5/7)
[29.0-96.3]
93.1 (27/29)
[77.2-99.2]
0.052
Other
46 87.5 (7/8)
[47.3-99.7]
97.4 (37/38)
[86.2-99.9]
95.7 (44/46)
[85.2-99.5]
0.321
PPA, positive percent agreement; N, Number of Specimens in each category
* A fisher’s exact t-test was used to calculate a p-value for the difference in PPA between ovarian and endometrial 
cancers
Table 5: Tissue of Origin Endometrial Test Performance According to Patient and Cancer 
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Tissue of Origin Endometrial Test Algorithm 
Development
The Pathwork Tissue of Origin Endometrial 
Test indicates whether Ovary or Endometrium is the 
more likely tissue of origin. The test relies on two 
distinct algorithms, one for standardization and one for 
classification. The  standardization  algorithm  utilizes  a 
set of 61 stable probe-sets to normalize the raw probe-
level  intensity  values  of  the  gene  expression  profiles 
under analysis and reduce technical variation incurred 
by different processing conditions. The standardization 
algorithm was developed by evaluating >5000 tissue 
specimens from a range of tissue types that were processed 
at 11 laboratories. The standardization expression values 
for each probe-set generated by the standardization 
algorithm are used by the Tissue of Origin Endometrial 
Test classification algorithm. The classification algorithm 
was developed using a database of 484 ovarian and 365 
endometrial specimens that had a known ovarian or 
endometrial cancer diagnosis based on clinical history 
and were from one of the included morphologies on the 
Tissue of Origin Endometrial Test panel (Table 1). A 
machine learning approach was used to select the optimal 
model for classifying ovarian and endometrial cancers. 
The optimal model consisted of a list of 375 probe-
sets (316 independent genes) and a set of coefficients 
that are combined to produce 2 similarity scores. The 2 
similarity scores correspond to the probability that the 
gene expression profile of the input specimen matches the 
expression profile of ovarian and endometrial cancers [16]. 
The standardization and classification algorithms were 
locked prior to initiation of clinical validation studies.
Tissue of Origin Endometrial Test Report
The Tissue of Origin Endometrial Test report (Figure 
1) is interpreted using the following guide to report 
interpretation: The Similarity Score (SS) is a measure 
of the similarity of the RNA expression pattern of the 
specimen to the RNA expression patterns of endometrial 
and ovarian tumor tissues. Two SS are generated, one 
for endometrial origin and one for ovarian origin. The 
scores add up to 100. The higher the SS, the more likely it 
represents the tissue of origin of the cancer. 
Clinical Validation Study Design
The Tissue of Origin Endometrial Test clinical 
validation study used Bayesian adaptive analysis to 
determine the design plan and sample sizes [33,34]. 
Details regarding the clinical validation study design and 
sample size estimates are provided in Supplementary 
Methods and Supplementary Table 1. Briefly, the study 
was designed to have no greater than 5% Type I error 
and at least 98% power to meet prespecified acceptance 
criteria. The criteria are based on the mean positive percent 
agreement (mean PPA) between the Test prediction and 
the available clinical diagnosis. The acceptance criteria 
were: at least 80% mean PPA and at least 65% lower 
bound of the corresponding 95% credible interval. These 
requirements were derived from analyses of the training 
data, requirements for clinical utility of the test, and 
practicality of obtaining sufficient number of specimens. 
The study design used three phases, commonly referred 
to as Looks. Look 1 uses ½ of the maximum sample size; 
Look 2 uses ¾ of the maximum sample size; and Look 3 
Reproducibility of the Tissue of Origin Endometrial Test
Study Comparison
Concordance
Percent (Ratio)
[95% Confidence Interval]
Discordance 
Percent (Ratio)
[95% Confidence Interval]
Intra-Site
Reproducibility
Section # 2 versus Section # 3
100 (15/15)
[78.2-100.0]
0 (0/15)
[0.0-21.8]
Section # 2 versus Section # 4
100 (16/16)
[79.4-100.0]
0 (0/16)
[0.0-20.6]
Section # 3 versus Section # 4
100 (15/15)
[78.2-100.0]
0 (0/15)
[0.0-21.8]
Overall
100 (46/46)
[92.3-100.0]
0 (0/46)
[0.0-7.7]
Inter-Site 
Reproducibility
PWDL versus EA
93.3 (28/30)
[77.9-99.2]
6.6 (2/30)
[0.8-22.1]
PWDL versus GLGC
96.6 (28/29)
[82.2-99.9]
3.4 (1/29)
[0.1-17.8]
EA versus  GLGC
93.1 (27/29)
[77.2-99.2]
6.9 (2/29)
[0.8-22.8]
Overall
94.3 (83/88)
[87.2-98.1]
5.7 (5/88)
[1.9-12.8]
PWDL, Pathwork Diagnostics Laboratory; EA, Expression Analysis; GLGC, GeneLogic
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uses the maximum sample size. The study design allowed 
for early termination based on intermediate analyses after 
each look. Study termination at each look could occur 
if the acceptance criteria were met or if the predicted 
probability of success at the maximum sample size, based 
on the data accumulated up to that point, was less than 5%.   
Reproducibility Study Design
The intra-site (precision) and inter-site 
reproducibility of the Tissue of Origin Endometrial Test 
was assessed as follows: For intra-site reproducibility 
(precision), three adjacent 10 µm thick sections from 
FFPE tissue blocks of 16 specimens (ovarian=8; 
endometrial=8) that gave an agreement with the known 
clinical diagnosis were processed simultaneously 
within the same run. For inter-site reproducibility, three 
adjacent 10 µm thick sections from FFPE tissue blocks 
of 30 specimens (ovarian=15; endometrial=15) that gave 
an agreement with the known clinical diagnosis were 
processed at each of the three laboratories in this study. 
Concordance in Tissue of Origin Endometrial Test results 
obtained from pairwise comparisons of the three sections 
was used as a measure of test reproducibility for both the 
intra-site and inter-site analysis. Details regarding sample 
size estimates for the reproducibility study are provided in 
Supplementary Methods. 
DATA ANALYSIS
Mean PPA and credible intervals are Bayesian 
parameters that were used as the primary endpoint for the 
Tissue of Origin Endometrial Test clinical validation study 
(see Supplementary Methods for details). Performance of 
the Test was measured as the positive percent agreement 
(PPA) which is defined as the percent agreement between 
the Tissue of Origin Endometrial Test result and the known 
clinical diagnosis. A receiver operator curve (ROC) was 
plotted and AUC was calculated using SigmaPlot 12 [35]. 
The DOR was calculated to provide a single indicator of 
test performance as described earlier [36]. For intra-site 
and inter-site reproducibility, results were considered 
concordant if the Tissue of Origin Endometrial test results 
from one section or site matched the result from another 
section or site. In both cases, an overall pairwise percent 
concordance in Tissue of Origin Endometrial Test results 
is reported. Kappa statistics for agreement were calculated 
for pairwise comparisons using R Version 2.11.1 (2010-
05-31) [37]. 
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